The abrogation of TPL2-mediated PSA promoter activation in AR-negative DU-145 prostate cancer cells suggests that TPL2-mediated ADI prostate cancer growth may be still dependent on AR activity. The gene discussed is AR; the disease is prostate carcinoma.